Olmesartan/Amlodipine Tablets 5/20 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
You & Life Sciences Co., Ltd.
MFDS item code 202000603 · Approved 2020.02.04
This product's status changed to Expired on 2025.02.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used for the treatment of patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It helps prevent cardiovascular complications by effectively lowering blood pressure.
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 milligrams once daily. This drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: For patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment (see Precautions for Use 2. Contraindications). ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Under 18 years of age: The safety and efficacy of this drug have not been established.
This medication can cause serious damage or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so discontinuation is required immediately upon confirmation of pregnancy. It should not be used in individuals with allergies to the active ingredients or similar compounds, those who are pregnant or breastfeeding, individuals with severe liver disease, heart valve disease, biliary obstruction, patients undergoing kidney dialysis, patients in shock, and certain diabetic patients. Patients with deficient fluid or salt may experience hypotension, so they should be closely monitored when starting this medication, and care should be taken as rapid vasodilation may also lead to hypotension. Caution is advised when administering to patients with weakened cardiac or kidney function, obstructive coronary artery disease, congestive heart failure, and those with reduced liver function. Various side effects such as dizziness, headache, hypotension, palpitations, dyspepsia, rash, and edema may occur; any abnormal symptoms should prompt immediate consultation with a medical professional. This medication may lower blood pressure, so when used in conjunction with other antihypertensive medications, careful monitoring of blood pressure, kidney function, and electrolyte status is necessary, and interactions may occur with certain drugs, which should be disclosed. This medication should not be taken during pregnancy, and if breastfeeding, caution is required as it may be excreted in breast milk and affect the infant, thus breastfeeding should be discontinued or medication should be stopped. Safety and efficacy have not been established for children under 18 years of age, and it is not recommended for them. Elderly patients may have reduced kidney and liver function, so treatment should start with a low dose and be approached cautiously. In the case of overdose, hypotension and cardiac function abnormalities may occur, requiring immediate medical attention, and treatment to raise blood pressure may be necessary if hypotension is severe. This medication should be stored away from direct sunlight and moisture, out of reach of children, and it is advisable not to transfer it to a different container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is recommended to store the medication at room temperature between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication for a long time.
White round film-coated tablets
30 tablets/PTP[((10 tablets/PTP) x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
You & Life Sciences Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.